JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carrasquillo, J. A.
Right arrow Articles by Dahut, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carrasquillo, J. A.
Right arrow Articles by Dahut, W.

Alendronate Does Not Interfere with 99mTc-Methylene Diphosphonate Bone Scanning

Jorge A. Carrasquillo, Millie Whatley, Valerie Dyer, William D. Figg and William Dahut

Nuclear Medicine Department, Warren G. Magnuson Clinical Center; and Clinical Pharmacokinetics Section, Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland



View larger version (149K):

[in a new window]
  		FIGURE 1. Posterior whole-body scan from patient 4. Metastatic sites to skull, ribs, and pelvis seen on baseline scan (left) are as well visualized on postalendronate scan (right).

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2001 by the Society of Nuclear Medicine.